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Background The efficacy and safety of mesh/graft in surgery for anterior or posterior pelvic 
organ prolapse is uncertain. 
Objectives To systematically review the efficacy and safety of mesh/graft for anterior or 
posterior vaginal wall prolapse surgery. 
Search strategy Electronic databases and conference proceedings were searched, 
experts and manufacturers contacted and reference lists of retrieved papers scanned. 
Selection criteria Randomised controlled trials (RCTs), non-randomised comparative 
studies, registries, case series involving at least 50 women, and RCTs published as conference 
abstracts from 2005 onwards. 
Data collection and analysis  One reviewer screened titles/abstracts, undertook data 
extraction, and assessed study quality. Data analysis was conducted for three subgroups: 
anterior, posterior, and anterior and/or posterior repair (not reported separately). 
Results Forty-nine studies involving 4569 women treated with mesh/graft were 
included. Study quality was generally high.  Median follow up was 13 months (range 1 to 51).  
In anterior repair, there was short-term evidence that mesh/graft (any type) significantly 
reduced objective prolapse recurrence rates compared with no mesh/graft (relative risk 0.48, 
95% CI 0.32-0.72). Non-absorbable synthetic mesh had a significantly lower objective 
prolapse recurrence rate (8.8%, 48/548) than absorbable synthetic mesh (23.1%, 63/273) and 
biological graft (17.9%, 186/1041), but a higher erosion rate (10.2%, 68/666) than synthetic 
mesh (0.7%, 1/147) and biological graft (6.0%, 35/581). There was insufficient information to 
compare any of the other outcomes regardless of prolapse type. 
Conclusion Evidence for most outcomes was too sparse to provide meaningful conclusions. 
Rigorous long-term RCTs are required to determine the comparative efficacy of using 
mesh/graft. 
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Pelvic organ prolapse (POP)1 is common and is seen in 50% of parous women.2 POP affects a 
woman’s quality of life by its local physical effects (pressure, bulging, heaviness or 
discomfort) or its effect on urinary, bowel or sexual function.  POP can be classified 
according to the compartment affected as: anterior vaginal wall prolapse (urethrocele, 
cystocele); posterior vaginal wall prolapse (rectocele, enterocele); prolapse of the cervix or 
uterus; and prolapse of the vaginal vault (which can only occur after prior hysterectomy).  A 
woman can present with prolapse of one or more of these sites.  The present review focuses 
on anterior and posterior vaginal wall prolapse. 
Current treatment options for anterior and posterior vaginal wall prolapse include 
pelvic floor muscle training (PFMT), use of pessaries (mechanical devices such as rings or 
shelves), and surgery including anterior or posterior colporrhaphy and site-specific defect 
repair.  Surgery can be augmented with implantation of mesh or graft materials which were 
first introduced in response to the high failure rate in both primary and secondary procedures:  
about 30% of women need an operation for recurrent prolapse.3 
Mesh or graft repair is theoretically suitable for any degree of symptomatic anterior 
and/or posterior vaginal wall prolapse.  In the UK, it has been most often used for women 
with recurrent prolapse.4  The technique for inserting mesh or graft varies widely between 
gynaecologists.  It can be individually cut, positioned and sutured using the surgeon’s 
preferred technique over the fascial (a ‘mesh inlay’), or the whole vagina can be surrounded 
by mesh/graft using introducers or commercial available kits (‘total mesh’).   
However, the efficacy and safety of mesh or graft to augment surgery for anterior or 
posterior pelvic organ prolapse is uncertain5, especially the occurrence and impact of 
mesh/graft erosion. The current study reports a rigorous systematic review of the evidence for 
efficacy and safety issues arising from the use of mesh/graft materials.  
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There are numerous types of mesh and graft materials available, which vary according 
to type of material, structure, and physical properties such as absorbability and pore size.  In 
the present review, the term ‘mesh’ was used for synthetic material and ‘graft’ was used for 
biological material; and mesh/graft were classified into four groups: absorbable synthetic 
mesh (e.g. polyglactin); biological graft (e.g. porcine dermis,); combined absorbable/non-
absorbable mesh/graft (termed ‘combined’ hereafter, e.g. polypropylene mesh coated with 
absorbable porcine collagen); and non-absorbable synthetic mesh (e.g. polypropylene). 
The aims of the present systematic review were to compare: (a) efficacy and safety 
between procedures using mesh/graft and no mesh/graft, and (b) efficacy and safety between 
different types of mesh/graft. 
This report is based on a systematic review commissioned and funded by the National 
Institute for Health and Clinical Excellence through its Interventional Procedures 
Programme.6  
 
Methods 
Search strategy 
Extensive highly sensitive electronic searches were conducted to identify reports (both full 
text papers and conference abstracts) of published and ongoing studies on the safety and 
efficacy of mesh/graft used in the repair of pelvic organ prolapse. Searches were restricted to 
publications from 1980 onwards and to those published in the English language.  Studies that 
reported only procedures without mesh/graft were not identified. Experts in the field were 
contacted and bibliographies of retrieved papers were scrutinised for additional reports. 
Eleven manufacturers were identified and contacted for properties of mesh/graft produced and 
for any studies related to mesh/graft. Full details of the search strategies used are available 
from the authors. 
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The databases searched were: Medline (1980-June  week 3 2007), Medline In-Process 
(3rd July 2007), Embase (1980 – 2007 week 26), Biosis (1985- 5th July 2007), Science 
Citation Index (1980 – 2nd July 2007), Cochrane Controlled Trials Register (The Cochrane 
Library, Issue 2 2007), ISI Conference Proceedings (1990 – 27th June 2007) as well as current 
research registers (National Research Register (Issue 2, 2007), Current Controlled Trials 
(April 2007) and Clinical Trials (April 2007)).  Additional databases searched for systematic 
reviews and other background information included the Cochrane Database of Systematic 
Reviews (The Cochrane Library, Issue 2, 2007), Database of Abstracts of Reviews of 
Effectiveness (June 2007) and the HTA Database (June 2007). Conference proceedings of 
major urogynaecological organisations (including American Urogynecologic Society, 
American Urological Association, European Association of Urology, European Society of 
Gynecological Endoscopy, Incontinence Society and International Urogynecological 
Association) for 2005 onwards were scrutinised for additional reports of randomised 
controlled trials (RCTs).  
 
Inclusion and exclusion criteria 
To try to ensure that all of the relevant studies wound be included, two reviewers (XJ & CG) 
screened the first 200 titles/abstracts independently. Any discrepancies between the screening 
results were discussed and consensus was reached. The main reviewer (XJ) then screened the 
remaining titles/abstracts using the agreed criteria. In cases of doubt, consensus was reached 
by discussing with the second reviewer (CG). Full text copies of all reports deemed to be 
potentially relevant were obtained and assessed by the main reviewer for inclusion. 
 Full-text RCTs, RCTs published as conference abstract from 2005 onwards, non-
randomised comparative studies, registry reports, and case series using mesh/graft with at 
least 50 women were sought. Case series/registries with a mean follow up of at least one year 
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were included for both efficacy and safety. Case series/registries with a mean follow up of 
less than one year were included for safety outcomes only. One year was considered a 
minimum adequate period of time in which to assess the efficacy of prolapse repair. 
The participants were women undergoing anterior and/or posterior vaginal wall 
prolapse surgery.  Studies of women with prolapse caused by pelvic trauma, congenital 
disease, or prolapse after creation of a neovagina were excluded.  Women undergoing other 
concomitant operations, such as hysterectomy or a continence procedure were considered 
providing the main indication for surgery was anterior or posterior prolapse. 
The interventions considered were anterior and/or posterior vaginal wall prolapse 
repair with mesh/graft.  There were no restrictions on type of mesh/graft or technique used. 
For RCTs and non-randomised comparative studies, the comparators were another operation 
technique using mesh/graft, or a type of surgery which did not involve mesh/graft. 
Primary outcomes for efficacy included persistent prolapse symptoms (subjective 
failure) and recurrent prolapse at original site (objective failure). For objective failure, 
outcomes measured by different systems, such as Pelvic Organ Prolapse-Quantification 
(POP-Q) system and Baden-Walker system, were combined. Secondary outcomes for 
efficacy included new prolapse at other sites that were free of prolapse at baseline, need for 
further surgery for prolapse (both recurrent and new), persistent urinary symptoms, persistent 
bowel symptoms, and persistent dyspareunia. For persistent urinary symptoms, bowel 
symptoms, and dyspareunia, only women having these symptoms at baseline were considered.  
Safety outcomes included blood loss, damage to surrounding organs during the 
operation, mesh/graft erosion, requirement for a further operation for mesh/graft erosion, new 
urinary incontinence, new bowel symptoms, new dyspareunia, infection, and other potentially 
serious adverse effects. For new urinary incontinence, bowel symptoms, and dyspareunia, 
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only women who were free of these symptoms at baseline were considered for these 
outcomes. 
 
Data extraction and quality assessment 
Data extraction and methodological quality assessment for the RCTs was conducted by two 
reviewers independently. The main reviewer extracted data and assessed the quality for the 
remaining studies. Two separate quality assessment checklists were used according to study 
design. Both checklists were developed by the Review Body for Interventional Procedures 
(ReBIP; Health Services Research Units at the University of Aberdeen and Sheffield), an 
independent review body that carries out systematic reviews for the Interventional Procedures 
Programme of the National Institute for Health and Clinical Excellence (NICE). The 
checklists were adapted from several sources.7-9  
 
Data analysis 
Data analysis was conducted for three subgroups of women according to the type of prolapse 
being repaired: anterior vaginal wall prolapse, posterior vaginal wall prolapse, and anterior 
and/or posterior vaginal wall repair (where the data were not reported separately). 
A meta-analysis of RCTs, using Cochrane Collaboration Review Manager (RevMan 
4.2) software, was conducted to directly compare the efficacy and safety of mesh/graft versus 
no mesh/graft and between different types of mesh/graft.  
Crude event rates (and 95% confidence intervals calculated by using binominal 
distribution approximation) for each of the intervention categories were tabulated by 
summing across studies for all outcomes, and also according to study design (RCT, non-
randomised comparative studies, case series/registries; data by study design not shown) to 
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facilitate qualitative assessment of potential heterogeneity of event rates across different study 
designs. 
In addition, Bayesian meta-analysis models were used to model the objective failure 
rates for the different interventions for anterior repair. This was the only outcome with 
sufficient data to generate a model. RCTs and non-randomised comparative studies were 
included in the model. Case series were not included to avoid bias from the strong assumption 
of the equivalence of studies implicit in the crude event rates.10  The specific type of model 
used was a (Bayesian) binomial random effects model. Differences between interventions, 
adjusted for study design, were assessed by the corresponding odds ratio and 95% credible 
interval (Crl). Crls are the Bayesian equivalent of confidence intervals. ‘Head to head’ 
indirect comparisons of the different mesh/graft types, adjusted for study design, was also 
conducted and reported as odds ratios and 95% CrIs.  WinBUGS software was used to 
produce the models.11 
Pre-specified subgroup analysis by different mesh types within non-absorbable mesh, 
i.e. Amid classification type I to IV,12 was not conducted because most studies did not report 
the type of mesh, resulting in insufficient data for subgroup analysis. Pre-specified subgroup 
analysis by ‘total mesh’ (use of introducers/commercial available kits) and ‘mesh inlay’ was 
not conducted due to the lack of data. Potential differences between primary repairs and 
recurrent prolapse repairs were not assessed because only one study reported exclusively on 
women having recurrent repairs, and the remainder did not report these subgroups separately. 
 
Results 
Number, type and quality of included studies 
From the initial 1633 publications identified by the literature search, 49 studies (reported in 
67 publications) were included, of which six were full-text RCTs,13-18 11 were RCTs available 
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as conference abstracts,19-29  seven were non-randomised comparative studies,30-36  one was a 
prospective registry,37 and 24 were case series with a minimum sample size of 50 women.38-61  
Six manufacturers provided data on mesh/graft properties and related studies, all of which had 
already been identified by our searches.  The screening process is summarised in Figure 1. 
For the 17 RCTs, 14 compared mesh/graft with no mesh/graft, and three13,22,26 compared 
different types of mesh/graft.  Appendix 1 shows details of study design, methods, 
participants, and interventions. Seven ongoing RCTs62-67 (Brandao: Personal communication, 
A Griffin, Johnson & Johnson, Aug 2007) and one ongoing registry68 were also identified. 
The included studies took place during the period 1996 – 2007 and in 12 countries.  
The median follow up was 13 months (range 1 to 51 months).  In total, 4569 women were 
treated with mesh or graft.  In studies providing this information, the mean age was 64 years 
(range 24 to 96 years). Seventy-two percent of repairs were primary procedures.  The most 
common use of mesh or graft was for anterior repair (54%, 2472/4569).  Overall, just over 
half of the studies used non-absorbable synthetic mesh (51%, 2320/4569) but for anterior 
repair alone and for posterior repair alone, biological graft was the most common alternative 
(46% (1124/2472) and 29% (121/417) respectively).  The surgical techniques for implanting 
mesh/graft varied considerably across studies. Fifty-six percent (1404/2497) of women had a 
concomitant procedure for urinary incontinence and 37% (953/2583) had a hysterectomy. 
The methodological quality was assessed for only the full text studies.  For the six 
RCTs, adequate approaches to sequence generation for randomisation were reported in all 
studies except one;13 concealment of treatment allocation was adequate in all RCTs except 
two;13,17  all follow-up periods were one year or more;  all studies used intention-to-treat 
analysis in that women were analysed in the groups to which they were randomised.  For the 
seven included non-randomised comparative studies, mean follow up was less than one year 
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in two studies.31,36 For the registry and case series, mean follow up was one year or more in 
17 studies.  The drop-out rates ranged from 0 to 30%. 
 
Anterior vaginal wall prolapse repair 
Thirty studies involving 2472 women provided data on the use of mesh/graft for anterior 
repair (five full text RCTs,13-15,17,18 seven RCTs available as conference abstracts,19,20,22-25,29 
four non-randomised comparative studies,30,33-35 one registry,37 and 13 case series38,44,46,49-52,55-
60). Four studies used absorbable synthetic mesh,13,17,18,59 14 studies used biological graft, 13-
15,22,24,25,30,33,35,50-52,57,60 one study used combined mesh/graft,38 and 14 studies used non-
absorbable synthetic mesh.19,20,22,23,29,33,34,37,44,46,49,55,56,58 The median follow-up time was 14 
months (range 1 to 38 months). Two RCTs13,22 and one non-randomised comparative study33 
compared different types of mesh/graft and the others compared mesh/graft with no 
mesh/graft. 
 
Efficacy 
There were too few data reported for most outcomes to draw reliable conclusions (Table 1).   
However, in 10 RCTs involving 1148 women, there was some evidence that 
mesh/graft (any type) was better than no mesh for preventing objectively determined 
recurrence of anterior prolapse (77/557 vs. 179/591; RR 0.48, 95% CI 0.32 to 0.72, Figure 2).  
When evidence from other study types was also considered, there was a trend in the crude 
objective failure rates (Table 2) with procedures not using mesh/graft having the highest 
failure rate (184/640, 29%, 95% CI 25 to 32%), followed by procedures with absorbable 
synthetic mesh (63/273, 23%, 95% CI19 to 28%), biological graft (186/1041, 18%, 95% CI16 
to 20%), and non-absorbable synthetic mesh (48/548, 9%, 95% CI  7 to 11%).  Compared to 
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procedures not using mesh/graft, the numbers need to treat (NNT) were 17 for absorbable 
synthetic mesh, 9 for biological graft, and 5 for non-absorbable synthetic mesh. 
Bayesian meta-analysis based on the evidence from the 10 RCTs and five non-
randomised comparative studies showed that procedures without mesh/graft had significantly 
higher objective failure rates than procedures with biological graft or non-absorbable 
synthetic mesh.  Comparisons between different types of mesh showed that non-absorbable 
synthetic mesh had statistically significantly lower objective failure rates than absorbable 
synthetic mesh (41/344 vs. 52/161; OR 0.23, 95% Crl 0.12 to 0.44) and biological graft 
(41/344 vs. 120/555; OR 0.37, 95% Crl 0.23 to 0.59) (Table 2).  
This trend appeared to be supported by the need for re-operation (for recurrent and 
new prolapse) which was highest in women treated with absorbable synthetic mesh (9% 
(16/174)), compared with 3% (9/280) for biological grafts and 1% (3/234) for non-absorbable 
synthetic mesh (Table 1). However, counter-intuitively, the re-operation rate for women with 
no mesh was lower (2% (2/85)); this estimate is based on one small study with short follow 
up (one year) and as such should be interpreted with caution.   
 
Safety 
For anterior repair, there were too few data on safety outcomes to identify or rule out 
important adverse effects related to the use of mesh/graft either because the studies were not 
sufficiently large or the adverse effects were rare (Table 3).   
There was some evidence to support the trends mentioned above (for objective failure 
rates and re-operation rates).  Mesh/graft erosion increased from 0.7% (1/147, 95% CI 0.1 to 
3.8) for absorbable synthetic mesh to 6.0% (35/581, 95% CI 4.4% to 8.3%) for biological 
graft, and to 10.2% (68/666, 95% CI 8.1 to 12.7%) for non-absorbable synthetic mesh.  
Women with a non-absorbable synthetic mesh repair were also most likely to require an 
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operation to remove it partially or completely because of mesh/graft erosion (23/347, 6.6%, 
95% CI 4.5 to 9.7) than for either absorbable synthetic mesh (1/35, 2.9%, 95% CI 0 to 3.3) or 
for biological graft 2.6%, (4/154, 95% CI 1 to 6.5).   
 
Posterior vaginal wall prolapse repair 
Only nine studies involving 417 women treated with mesh/graft reported data on the use of 
mesh/graft in posterior repair (two full-text RCTs,16,17 one RCT available as a conference 
abstract,26 two non-randomised comparative studies,31,32 one registry report,37 and three case 
series53-55).  Three studies used absorbable synthetic mesh,17,26,32  three used biological 
graft,16,31,53 two used combined mesh/graft,26,54 and two studies used non-absorbable synthetic 
mesh.37,55 No RCTs or non-randomised comparative studies compared different types of 
mesh/graft for posterior repair.  The median follow up was 12 months (range 1 to 17 months). 
 There were too few data reported for any of the outcomes to draw reliable conclusions 
or to carry out further statistical analyses (Table 4 and 5).   
 
Anterior and/or posterior vaginal wall prolapse repair 
Fourteen studies involving 1680 women treated with mesh/graft reported data on the use of 
mesh/graft in anterior and/or posterior repair (three RCTs available as conference 
abstracts,21,27,28 one non-randomised comparative study,36 one registry report,37 and nine case 
series39-43,45,47,48,61).  One study used absorbable synthetic mesh,21 none of the studies used 
biological graft, one study used a combined mesh/graft,45 10 studies used non-absorbable 
synthetic mesh,27,28,37,40-43,47,48,61 and two studies used more than one of the above types of 
mesh/graft.36,39 None of the RCTs or non-randomised comparative studies compared different 
types of mesh or grafts. The median follow up was 13 months (range 1 to 51 months).  
 10
290 
291 
292 
293 
294 
295 
296 
297 
298 
299 
300 
301 
302 
303 
304 
305 
306 
307 
308 
309 
310 
311 
312 
313 
314 
 For objective failure, there was a trend in the crude events rates (Table 6) with 
procedures not using mesh/graft having the highest failure rate (27/109, 25%, 95% CI 18 to 
34%), followed by procedures with absorbable synthetic mesh (2/26, 8%, 95% CI 2 to 24%), 
combined mesh/graft (11/143, 8%, 95% CI 4 to 13%), and non-absorbable synthetic mesh 
(41/645, 6%, 95% CI 5 to 9%).  Compared to procedures not using mesh/graft, the numbers 
need to treat (NNT) were six for absorbable synthetic mesh, six for biological graft, and five 
for non-absorbable synthetic mesh. There were too few data (only three RCTs) to conduct 
Bayesian meta-analysis and too few data on any of the other outcomes to identify or rule out 
important adverse effects related to the use of mesh/graft (Table 6 and 7).  
 
Discussion 
Summary of the evidence 
In anterior vaginal wall prolapse repair, there was some short-term evidence suggesting that 
mesh/graft (any type) could reduce objective prolapse recurrence rates compared with no 
mesh/graft.  In the comparison between different types of mesh/graft, non-absorbable 
synthetic mesh had statistically significantly lower objective failure rates than absorbable 
synthetic mesh and biological graft.  However, there was no information about efficacy in the 
longer term.   
While there might be some evidence of differences in objective efficacy related to the 
use of mesh, these must be considered alongside any safety concerns.  There was some 
evidence to suggest that mesh/graft may cause problems with erosion and a subsequent need 
for operations to remove the foreign material.  However, the numbers were too few to conduct 
statistical analyses to compare the erosion rates between different types of mesh or graft.   
 
Methodology 
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In the present review, RCTs, non-randomised comparative studies, and large case series 
(sample size ≥ 50) were included.  The results were considered generalisable as the majority 
of studies recruited participants from routine practice without restriction on the severity of 
prolapse or other patient characteristics.   
As this review focused on the efficacy and safety of treatments involving mesh/graft, 
studies reporting only procedures without mesh/graft were not systematically searched for.  
Data on no-mesh/graft treatments came only from the control groups of RCTs and non-
randomised comparative studies only. Therefore the results for ‘no-mesh/graft’ were not 
derived from a comprehensive literature search and should be interpreted with caution. 
However, considering that there was insufficient evidence for most outcomes involving 
procedures with mesh/graft, including studies reporting only procedures without mesh/graft 
would increase the accuracy of the estimates for the ‘no mesh/graft’ group, but would not 
impact on the mesh/graft comparisons or change the conclusions of the review. 
Categorising some of the reported outcomes was problematic.  For instance, cut-off 
points used to determine objective failure rates varied between studies.  All types of infections 
such as urinary tract infection, wound infection and pelvic abscess were grouped together.  
Apart from conducting meta-analysis of the RCTs in RevMan to compare the efficacy 
and safety between different types of mesh/graft, crude event rates from the RCTs and non-
randomised comparative studies were calculated by treating each arm in effect as a case series.  
The rate from each arm was then combined with those from other such ‘case series’ derived 
from comparative studies and from case series reporting mesh/graft. This was considered an 
alternative way to compare all of the available mesh/graft types.  The analyses were adjusted 
to account for bias from non-randomised comparative studies and case series, which are more 
prone to systematic biases than RCTs.  
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It was impossible to determine whether safety and efficacy of mesh differs between 
primary repair and recurrent prolapse repair. Of the 49 included studies, 12 reported a case 
mix (72% primary and 28% secondary operations) in 1359 women but no study reported the 
outcome data separately for the two groups.  These data, however, suggest that many 
gynaecologists are already using mesh in women for primary repair.  Only one31 of the 
included studies reported exclusively on women having recurrent repair (a small comparative 
study of only 12 women in each of two arms).   
 
Efficacy 
One year was considered as an adequate minimum period of time to assess the efficacy of 
prolapse repair.  However, even one year outcomes are too early to judge whether prolapse 
surgery is successful in the longer term.  The mean time to first re-operation is reported in the 
literature as 12 years,3 and therefore failure at one year should not be regarded as an adequate 
representation of efficacy.  Prospective studies would require extended follow up to assess 
meaningful mesh/graft failure.   
The conundrum in prolapse surgery is that objective prolapse recurrence is not 
necessarily related to continuation of prolapse symptoms (subjective failure). It is increasingly 
recognised that in prolapse surgery, subjective failure is a more appropriate outcome measure 
of efficacy than objective failure. It is also recognised that criteria for measuring such 
subjective prolapse outcomes are difficult to quantify and the most appropriate methods are 
still being evaluated.  In the present review, only a few studies reported data on subjective 
prolapse symptoms and other genitourinary symptoms of importance to women (urinary, 
bowel and sexual function).   
 
Safety 
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The clinical importance of mesh/graft erosion was difficult to assess.  The diagnosis was both 
problematic as different authors used different definitions (mesh erosion, vaginal mesh 
extrusion, minor mesh exposure), and its clinical impact controversial as some gynaecologists 
operated on erosions15,18,33,34,40-49,54,61 whereas others treated erosions with debridement, 
vaginal oestrogens, antiseptics or antibiotics.36,41,48,57,60 
One of the anecdotally cited contra-indications for the use of mesh is the likelihood of 
dyspareunia.  This outcome is more problematic to measure because some women are not 
sexually active, but not all studies take this factor into account when reporting their sexual 
function data.  Secondly, some women may be sexually inactive because of their prolapse 
surgery (especially when the outcome is measured within 6 months of operation).  Thirdly, 
many studies do not measure or report this outcome at all.  Two outcomes were used in the 
present review to make the best estimates: persistent dyspareunia in women having 
dyspareunia at baseline (efficacy), and de novo dyspareunia in women without dyspareunia at 
baseline (safety). However, few studies reported such data.   
Some adverse effects occurred infrequently: in consequence their estimated event rates 
may be prone to random error.  Some of the safety outcomes, such as blood loss, may not be 
due only to the repair of vaginal wall prolapse, but also to concomitant procedures such as 
those for urinary incontinence or hysterectomy. 
Although the numbers were not sufficient to perform meaningful sub-group analyses 
by ‘total mesh’ (use of introducers/commercial available kits) and ‘mesh inlay’, the use of 
blind introducers has given rise to some concern.  These have only been used to date with 
non-absorbable synthetic mesh.  In total, there were 6/476 (1.3%) events of damage to 
surrounding organs for anterior repair, 6/276 (2.2%) for posterior repair and 16/684 (2.3%) 
for anterior and/or posterior repair, giving a total of 28/1436 (1.9%).  Of the 28 events, half 
were associated with an introducer kit.     
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Conclusions and implications 
In general, the evidence for most efficacy and safety outcomes was too sparse to provide 
meaningful conclusions about the use of mesh/graft in anterior and/or posterior vaginal wall 
prolapse surgery.   
 Rigorous RCTs are required to determine the comparative efficacy of using mesh/graft 
and its optimal place in clinical practice.  The RCTs should primarily compare the subjective 
failure rate in procedures using mesh/graft versus those without mesh/graft, and between 
different types of mesh/graft; use validated patient-reported outcome measures; have 
sufficient power to detect clinically meaningful differences in both efficacy and safety; and 
have the capacity to assess outcomes in the long term (at least 5 years), including cost-
effectiveness.   
In addition, prospective data collection should be considered in which the operative 
and clinical details of women undergoing prolapse surgery with mesh/graft can be recorded so 
that sufficient efficacy and safety data can be gathered to guide the use of mesh or grafts in 
the future.   
 
(Word count: 4088) 
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Table 1 Efficacy of anterior repair, summary of crude event rates (95% CI, any study design), by type 
of mesh/graft  
 No mesh Absorbable 
synthetic mesh 
Biological graft Non-absorbable 
synthetic mesh 
Subjective failure 19/179  
(10.6%, 6.9 - 16.0) 
5/112  
(4.5%, 1.9 - 10.0) 
36/486 
 (7.4%, 5.4 - 10.1) 
1/55  
(1.8%, 0 - 6.5) 
Objective failure 184/640  
(28.8%, 25.4 - 32.4)
63/273  
(23.1%, 18.5 - 28.4)
186/1041 
 (17.9%, 15.7 - 20.3) 
48/548 
 (8.8%, 6.7 - 11.4) 
De novo prolapse - - 8/58  
(13.8%, 7.2 - 24.9) 
8/45  
(17.8%, 9.3 - 31.3) 
Further operation 
needed* 
2/85 
 (2.4%, 0.6 - 8.2) 
16/174  
(9.2%, 5.7 - 14.4) 
9/280  
(3.2%, 1.7 - 6.0) 
3/234  
(1.3%, 0.4 - 3.7) 
Persistent urinary 
symptoms 
9/10  
(90.0%, 59.6 - 98.2)
5/49  
(10.2%, 4.4 - 21.8) 
13/14  
(92.9%, 68.5 - 98.7) 
17/44  
(38.6%, 25.8 - 53.4)
Persistent bowel 
symptoms 
- - - - 
Persistent 
dyspareunia  
- - - - 
674 
675 
* surgery for prolapse (recurrent or de novo) 
- No studies reported this outcome 
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Table 2 Bayesian meta-analysis models (above)a and indirect comparison (below)a, 
anterior repair: objective failure (recurrent prolapse at original site)  
676 
677 
678  
Categories nb Nb OR (adjusted for study design) 95% CrIc 
No mesh/graft  184 640 Reference technique - 
Absorbable synthetic mesh 52 161 0.82 0.50 to 1.32 
Absorbable biological graft 120 555 0.51* 0.36 to 0.72 
Non-absorbable synthetic mesh 41 344 0.19* 0.12 to 0.30 
679 
680 
 
 
Comparisons OR 95% CrIc 
Absorbable biological graft versus absorbable synthetic mesh 0.64 0.36 to 1.06 
Non-absorbable synthetic mesh versus absorbable synthetic mesh 0.23* 0.12 to 0.44 
Non-absorbable synthetic mesh versus absorbable biological graft 0.37* 0.23 to 0.59 
681 
682 
683 
684 
685 
686 
687 
 
 
*Statistically significant 
aBased on RCTs and non-randomised comparative studies only; 
bn = cumulative number of patients experiencing the event, N = cumulative number of patients 
analysed by the studies. 
cCrI.  Credible interval with 95% probability of containing the true OR 
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689 
Table 3 Safety of anterior repair, summary of crude event rates (95% CI, any study design), by 
type of mesh/graft  
 No mesh Absorbable 
synthetic mesh 
Biological graft Non-absorbable 
synthetic mesh 
Blood transfusion 1/88  
(1.1%, 0.2 - 6.2) 
0/147  
(0%, 0 - 2.5) 
3/198  
(1.5%, 0.5 - 4.4) 
4/161  
(2.5%, 1.0 - 6.2) 
Damage to surrounding 
organs 
0/19  
(0%, 0 - 16.8) 
0/112  
(0%, 0 - 3.3) 
0/94  
(0%, 0 - 3.9) 
6/251  
(2.4%, 1.1 - 5.1) 
Mesh/graft erosion Not applicable 1/147 
(0.7%, 0.1 - 3.8) 
35/581 
(6.0%, 4.4 - 8.3) 
68/666  
(10.2%, 8.1 - 12.7) 
Operation for 
mesh/graft erosion 
Not applicable 1/35  
(2.9%, 0 - 3.3) 
4/154  
(2.6%, 1.0 - 6.5) 
23/347  
(6.6%, 4.5 - 9.7) 
De novo urinary 
symptoms 
- 0/63  
(0%, 0 - 5.7) 
3/42  
(7.1%, 2.5 - 19.0) 
3/44  
(6.8%, 2.3 - 18.2) 
De novo bowel 
symptoms 
- - - - 
De novo dyspareunia - - - 4/11  
(36.4%, 15.2 - 64.6) 
Infection  4/142  
(2.8%, 1.1 - 7.0) 
0/112  
(0%, 0 - 3.3) 
5/477  
(1.0%, 0.4 - 2.4) 
11/558  
(2.0%, 1.1 - 3.5) 
Other serious adverse 
effects 
1/93  
(1.1%, 0.2 - 5.8) 
0/35  
(0%, 0 - 9.9) 
2/212  
(0.9%, 0.3 - 3.4) 
4/248  
(1.6%, 0.6 - 4.1) 
690 
691 
 
- No studies reported this outcome 
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692 
693 
Table 4  Efficacy of posterior repair, summary of crude event rates (95% CI, any study design), by type 
of mesh/graft  
 No mesh Absorbable 
synthetic mesh 
Biological graft Combined 
mesh/graft 
Non-absorbable 
synthetic mesh 
Subjective failure 9/60 
(15.0%, 8.1 to 26.1) 
- 9/78 
(11.5%, 6.2 - 20.5)
- - 
Objective failure 18/142 
(12.7%, 8.2 - 19.1) 
6/70 
(8.6%, 4.0 - 17.5) 
19/93 
(20.4%, 13.5 - 29.7)
- 2/31 
(6.5%, 1.8 - 20.7)
De novo prolapse - - - - - 
Further operation 
needed* 
3/70 
(4.3%, 1.5 - 11.9) 
- 2/29 
(6.9%, 1.9 - 6.9) 
- - 
Persistent urinary 
symptoms 
- - - - - 
Persistent bowel 
symptoms 
19/58 
(32.8%, 22.1 - 45.6) 
- 14/82 
(17.1%, 10.5 - 26.6)
5/43 
(11.6%, 5.2 - 24.6) 
- 
Persistent 
dyspareunia  
- - 5/14 
(35.7%, 16.3 - 61.2)
- - 
694 
695 
696 
* surgery for prolapse (recurrent or de novo) 
- No studies reported this outcome 
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697 
698 
Table 5  Safety of posterior repair, summary of crude event rates (95% CI, any study design), by type of 
mesh/graft  
 No mesh Absorbable 
synthetic mesh 
Biological graft Combined 
mesh/graft 
Non-absorbable 
synthetic mesh 
Blood transfusion 3/79  
(3.8%, 1.3 to 10.6)
0/5 
 (0%, 0 to 43.4) 
1/31  
(3.2%, 0.6 to 16.2) 
0/90  
(0%, 0 to 4.1) 
1/71 
 (1.4%, 0.2 to 7.6) 
Damage to 
surrounding organs 
2/79 
 (2.5%, 0.7 to 8.8) 
0/5  
(0%, 0 to 43.4) 
1/31 
 (3.2%, 0.6 to 16.2) 
0/90  
(0%, 0 to 4.1) 
3/71 
 (4.2%, 1.4 to 11.7)
Mesh/graft erosion Not applicable - 0/28  
(0%, 0 to 12.1) 
16/115  
(13.9%, 8.7 to 12.1)
2/31  
(6.5%, 1.8 to 20.7)
Operation for 
mesh/graft erosion 
Not applicable - - 11/90  
(12.2%, 7.0 to 20.6)
- 
De novo urinary 
symptoms 
- - - - - 
De novo bowel 
symptoms 
- - - 2/45 
 (4.4%, 1.2 to 14.8)
1/29 
 (3.4%, 0.6 to 17.2)
De novo dyspareunia - 4/25  
(16.0%, 6.4 to 34.7)
- 2/36  
(5.6%, 1.5 to 18.1)
- 
Infection  13/94  
(13.8%, 8.3 to 22.2)
0/5  
(0%, 0 to 43.4) 
7/48  
(14.6%, 7.2 to 27.2) 
- 4/106 
 (3.8%, 1.5 to 9.3) 
Other serious adverse 
effects 
- - - - - 
699 
700 
 
- No studies reported this outcome 
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702 
Table 6 Efficacy of anterior and/or posterior repair, summary of crude event rates (95% CI, 
any study design), by type of mesh/graft  
 No mesh Absorbable 
synthetic mesh 
Combined 
mesh/graft 
Non-absorbable 
synthetic mesh 
Subjective failure 14/34 
(41.2%, 26.4 - 57.8)
14/32 
(43.8%, 28.2 - 60.7)
- 0/148  
(0%, 0 - 2.5) 
Objective failure 27/109 
(24.8%, 17.6 - 33.6)
2/26  
(7.7%, 2.1 - 24.1) 
11/143 
 (7.7%, 4.3 - 13.2) 
41/645  
(6.4%, 4.7 - 8.5) 
De novo prolapse - - - - 
Further operation 
needed* 
- - - 7/161  
(4.3%, 2.1 - 8.7) 
Persistent urinary 
symptoms 
- - - 46/203  
(22.7%, 17.4 - 28.9)
Persistent bowel 
symptoms 
- - - 1/21  
(4.8%, 0.8 - 22.7) 
Persistent 
dyspareunia  
- - 1/10  
(10.0%, 1.8 - 40.4) 
- 
703 
704 
705 
706 
* surgery for prolapse (recurrent or de novo) 
 
- No studies reported this outcome 
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Table 7 Safety of anterior and/or posterior repair, summary of crude event rates (95% CI, any study design), by 
type of mesh/graft  
 No mesh Combined mesh/graft Non-absorbable synthetic 
mesh 
Blood transfusion 1/35 
 (2.9%, 0.5 - 14.5) 
- 11/810 
 (1.4%, 0.8 - 2.4) 
Damage to surrounding organs - 4/143  
(2.8%, 1.1 - 7.0) 
12/541 
 (2.2%, 1.3 - 3.8) 
Mesh/graft erosion Not applicable 9/143  
(6.3%, 3.3 - 11.5) 
62/1119 
(5.5%, 4.3 - 7.0) 
Operation for mesh/graft erosion Not applicable 6/143  
(4.2%, 1.9 - 8.9) 
45/1098 
 (4.1%, 3.1 - 5.4) 
De novo urinary symptoms - - 34/355 
 (9.5%, 6.9 - 13.1) 
De novo bowel symptoms - - 1/47  
(2.1%, 0.4 - 11.1) 
De novo dyspareunia - 10/78 
 (12.8%, 7.1 - 22.0) 
3/42  
(7.1%, 2.5 - 19.0) 
Infection  - - 33/661 
 (5.0%, 3.6 - 6.9) 
Other serious adverse effects - - 3/278  
(1.1%, 0.4 - 3.1) 
709 
710 
711 
712 
 
- No studies reported this outcome 
 
 
 31
 32
713 
714 
715 
716 
Figure 1 Flow diagram for screening process. 
 
Potentially relevant reports identified and 
screened for retrieval (n=1633) 
 
Figure 2 
 717 
Reports retrieved for more detailed 
evaluation (n=446):  
Studies included (n=49, in 67 reports):  
6 full text RCTs,  
11 RCTs available as conference abstract, 
7 non-randomised comparative studies,  
24 case series with sample size ≥ 50 (18 mean follow-up ≥ one year    
and 8 < one year)  
1 registry (mean follow up < one year) 
Excluded reports (n=397): 
Case series with sample size < 50 (n=43), 
Results for anterior and/or posterior repair were 
not presented separately from those of 
uterine and/or vault prolapse (n=13), 
Case report without safety data (n=7), 
Not a report of primary research (n=6), 
No relevant outcomes reported or no data (n=5), 
Prolapse repair did not use mesh/graft (n=14),  
Repair not for genital prolapse (n=12), 
Other reasons, e.g. reviews (n=297) 
Excluded reports (n=1187): not meeting inclusion 
criteria, e.g. studied surgery for uterine or vault 
prolapse 
Appendix S1 (online) Details of the included studies  718 
ID N Age, y, median 
(range) or 
mean (range) 
Primary/ 
secondary repair, 
n 
Mesh/graft Anterior repair only/
posterior only/both, 
n 
Concomitant operation Follow-up, median 
(range) or mean 
(SD) 
Outcomes 
reported 
 
Anterior vaginal wall prolapse repair 
 
RCT 
 
        
De Ridder 
200213 
 
A, 65 
B, 69 
A, 70 (24-86) 
B, 70 (36-83) 
NR A, absorbable biological graft (porcine dermis) 
B, absorbable synthetic graft (polyglactin) 
A, 55/0/10 
B, 56/0/13 
Hysterectomy: 
A, 38/65; B 41/69 
A, 25m (5) 
B, 26m (6) 
Efficacy  
Gandhi 200514 
 
 
 
A, 76 
B, 78 
A, 65 (12) 
B, 66 (12) 
NR A, absorbable biological graft (cardaveric fascia lata) 
B, no mesh 
A, 1/0/75 
B, 5/0/73 
Incontinence: 
A, 51/76; B, 43/78 
Hysterectomy: 
A, 37/76; B, 37/78 
13m (1 – 50) Efficacy  
Meschia 200715 
 
 
 
A, 98 
B, 103 
A, 65 (8) 
B, 65 (9) 
A 100/0 
B, 106/0 
A, absorbable biological graft (porcine dermis) 
B, no mesh 
A, 33/0/67 
B, 39/0/67 
Incontinence: 
A, 4/100; B 3/106 
Hysterectomy: 
A+B, 188/206 
1y Safety  
Efficacy  
Sand 200117 
 
 
 
 
A, 73 
B, 70 
A, mean 65 
B, mean 63 
A, 55/18 
B, 49/21 
A, absorbable synthetic mesh (polyglactin) 
B, no mesh 
A, 8/0/65 
B, 3/0/67 
Incontinence: 
A, 58/73; B, 52/70 
Hysterectomy: 
A, 36/73; B 39/70 
1y Safety  
Efficacy  
Weber 200118 
 
 
A, 35 
B, 39 
C, 35 
A, 66 (11) 
B, 66 (11) 
C, 62 (13) 
NR A, absorbable synthetic mesh (polyglactin) 
B, no mesh 
C, no mesh 
NR NR 23m (5 – 44) Safety  
Efficacy  
RCT (abs.) 
 
        
Al-Nazer 200719 
 
 
A, 20 
B, 20 
NR NR A, non-absorbable synthetic mesh (polypropylene, 
Gynemesh PS) 
B, no mesh 
NR NR 1y Efficacy  
Ali 200620 
 
 
 
A, 54 
B, 54 
NR NR A, non-absorbable synthetic mesh (polypropylene, 
Gynemesh PS) 
B, no mesh 
NR NR 6m Safety 
Efficacy  
Cervigni 200722 
 
 
A, 93 
B, 87 
A+B, mean 64 NR A, non-absorbable synthetic mesh (polypropylene, 
Gynemesh) 
B, absorbable biological graft (human dermis) 
NR NR 6 – 28m Safety 
Efficacy  
 1 
ID N Age, y, median 
(range) or 
mean (range) 
Primary/ 
secondary repair, 
n 
Mesh/graft Anterior repair only/
posterior only/both, 
n 
Concomitant operation Follow-up, median 
(range) or mean 
(SD) 
Outcomes 
reported 
Hiltunen 200623 
 
 
A, 105 
B, 97 
NR NR A, non-absorbable synthetic mesh (polypropylene, 
Parietene light) 
B, no mesh 
NR NR 1y Safety 
Efficacy  
Hviid 200524 
 
 
A, 19 
B, 20 
A+B, 59 (40-
84) 
NR A, absorbable biological graft (porcine dermis) 
B, no mesh 
NR NR 3m Safety 
Efficacy  
Kocjancic 
200725 
 
A, 85 
B, 91 
NR NR A, absorbable biological graft (porcine dermis) 
B, no mesh 
NR NR 2y Safety 
Efficacy  
Nguyen 200729 
 
 
A, 31 
B, 32 
NR NR A, non-absorbable synthetic mesh (polypropylene, 
Perigee) 
B, no mesh 
NR NR 6m Safety 
Efficacy  
Non-randomised comparative studies 
 
Chaliha 200630 
 
 
A, 14 
B, 14 
A, 70 (51-86) 
B, 60 (47-79) 
A, 12/2 
B, 12/2 
A, absorbable biological graft (small intestine 
submucosa) 
B, no mesh 
A, 14/0/0 
B, 14/0/0 
Incontinence: 
A, 0/14; B, 0/14 
2y Safety  
Efficacy  
Handel 200733 
 
 
 
A, 56 
B, 25 
C, 18 
NR A, 36/20 
B, 24/1 
C 17/1 
A, absorbable biological graft (porcine dermis) 
B, non-absorbable synthetic mesh (polypropylene, not 
reported trade name) 
C, no mesh 
A, 18/0/38 
B, 7/0/18 
C, 6/0/12 
Incontinence: 
A 48/56; B, 20/25; C 9/18 
Hysterectomy: 
A 46/56; B, 25/25; C, 18/18 
All, 14m (2 – 46) 
A, mean 17m 
B, mean 13m 
C, mean 9m 
Safety  
Efficacy  
Julian 199634 
 
 
 
A, 12 
B, 12 
A, 63 (37-82) 
B, 66 (46-78) 
A, 0/12 
B, 0/12 
A, non-absorbable synthetic mesh (polypropylene, 
Marlex) 
B, no mesh 
NR NR 2y Safety  
Efficacy  
Leboeuf 200435 
 
 
A, 24 
B, 19 
A+B, 65 (33-
91) 
NR A, absorbable biological graft (porcine dermis) 
B, no mesh 
A+B, 8/0/35 NR Mean 15m Safety  
Efficacy  
Registry  
 
        
Altman 200737 
 
106 68 (10) 18/88 Non-absorbable synthetic mesh (polypropylene, Prolift) 106/0/0 NR Registered in a 6m 
period  
Safety  
Case series 
 
        
Cronje 200638 
 
50 65 NR Combined mesh/graft (polypropylene and polyglactine) NR NR 12m (1-50) Safety 
Efficacy 
De Tayrac 
200644 
55 63 (11) 59/4 non-absorbable synthetic mesh (polypropylene, 
Gynemesh) 
45/0/10 Incontinence: 22/63 
Hysterectomy: 52/63 
37 (10) Safety   
Efficacy  
 2 
ID N Age, y, median 
(range) or 
mean (range) 
Primary/ 
secondary repair, 
n 
Mesh/graft Anterior repair only/
posterior only/both, 
n 
Concomitant operation Follow-up, median 
(range) or mean 
(SD) 
Outcomes 
reported 
Deffieux 200746 
 
138 62 (30-83) NR Non-absorbable synthetic mesh (polypropylene, 89 
Gynemesh, 49 Gynemesh-Soft) 
118/0/20 Incontinence: 87/138 
Hysterectomy: 103/138 
6m Safety  
Flood 199849 
 
 
142 65 (37-87) 120/22 Non-absorbable synthetic mesh (polypropylene, Marlex) NR Hysterectomy: 94/142 3.2y (6w – 12y) Safety 
Efficacy  
Frederick 
200550 
 
251 66 (31-90) 226/25 Absorbable biological graft (solvent dehydrated fascia 
lata) 
158/0/90  Incontinence: 251/251 
Hysterectomy: 28/248 
22m (6 – 61) Safety 
Efficacy  
Gomelsky 
200451 
 
70 NR NR Absorbable biological graft (porcine dermis) NR Incontinence: 65/70 24m (12 – NR) Safety 
Efficacy  
Kobashi 200252 
 
132 62 (35-90) NR Absorbable biological graft (solvent dehydrated fascia 
lata) 
NR NR 12m (6-28) Safety 
Efficacy  
Milani 200555  
 
32 63 (49-82) NR Non-absorbable synthetic mesh (polypropylene, 
Prolene) 
32/0/0 NR 17m (3 – 48) Safety 
Efficacy  
Petros 200656 
 
 
98 65 (40-86) 42/48 Non-absorbable synthetic mesh (NR materia, 
multifilament, Tissue Fixation System)  
NR NR 8m (3 – 15) Safety  
Powell 200457 
 
 
58 NR NR Absorbable biological graft (donor or autologousfascia 
lata) 
A, 17/0/22 
B, 11/0/8 
Incontinence: 41/58 
Hysterectomy: 14/58 
25m (12 – 57) Safety 
Efficacy  
Rodriguez 
200558 
 
98 65 (40-86) NR Non-absorbable synthetic mesh (soft polypropylene, NR 
trade name) 
6/0/92 Incontinence: 98/98 
 
Assume 3m Safety  
Safir 199959 
 
112 65 (35-96) 70/60 Absorbable synthetic mesh (polyglacolic acid) 31/0/81 Hysterectomy: 22/112 21m (6 – 42) Safety 
Efficacy  
Simsiman 
200660 
89 60 (26-82) NR Absorbable biological graft (porcine dermis) NR Incontinence: 41/89 
Hysterectomy: 48/89 
24m (6 – 44) Safety 
Efficacy  
 
Posterior vaginal wall prolapse repair 
 
RCT 
 
        
Paraiso 200616 
 
 
 
 
A, 31 
B, 37 
C, 37 
A, 60 (11) 
B, 61 (12) 
C, 62 (9) 
NR A, absorbable biological graft (porcine dermis) 
B, no mesh 
C, no mesh 
A, 0/12/19 
B, 0/17/20 
C, 0/11/26 
Continence: 
A, 15/31; B, 17/37; C, 17/37
Hysterectomy: 
A, 13/31; B, 12/37; C 14/37 
16m (4 – 34) Safety  
Efficacy  
 3 
ID N Age, y, median 
(range) or 
mean (range) 
Primary/ 
secondary repair, 
n 
Mesh/graft Anterior repair only/
posterior only/both, 
n 
Concomitant operation Follow-up, median 
(range) or mean 
(SD) 
Outcomes 
reported 
Sand 200117 
 
 
A, 65 
B, 67 
NR NR A, absorbable synthetic mesh (polyglactin) 
B, no mesh 
A, 0/0/65 
B, 0/0/67 
NR 1y Safety  
Efficacy  
RCT (abs.) 
 
        
Lim 200626 
 
 
 
 
A, 25 
B, 9 
C, 31 
A, 58 (10) 
B, 67 (9) 
C, 55 (13) 
NR A, semi absorbable mesh/graft (polypropylene-
polyglactin) 
B, absorbable synthetic mesh (polyglactin) 
C, no mesh 
NR NR A, 14m (9) 
B, 12 (12) 
C, 12 (10) 
Safety 
Efficacy  
Non-randomised comparative studies  
 
Altman 200431  
 
 
A, 17 
B, 15 
A, 60 (42-75) 
B, 59 (43-68) 
NR A, absorbable biological graft (porcine dermis) 
B, no mesh 
A, 0/16/1 
B, 0/8/3 
Hysterectomy:  
A, 2/17; B 2/15 
6m Safety  
Efficacy  
Castelo-Branco 
199832 
 
 
 
A, 5 
B, 5 
A, 57 (7) 
B, 56 (8)  
NR A, absorbable synthetic mesh (polyglacolic acid) 
B, no mesh 
A, 0/3/2 
B, 0/1/4 
Incontinence: 
A, 1/5; B, 1/5 
Hysterectomy: 
A, 1/5; B, 3/5 
1y  
Registry  
 
        
Altman 200737 
 
 
71 68 (10) 48/23 Non-absorbable synthetic mesh (polypropylene, Prolift) 0/71/0 NR Registered in a 6m 
period 
Safety  
Case-series 
 
        
Kobashi 200553  
 
 
 
73 
 
 
31-86 NR Absorbable biological graft (solvent-dried fascia lata) NR NR 14m (6 – 23) Safety  
Efficacy  
Lim 200554 90 59 (31-85) NR Combined mesh/graft (polypropylene-polyglactin) 
 
0/75/15 Incontinence: 69/90 
 
6m Safety  
Milani 200555 
 
 
 
 
 
31 63 (50-80) NR Non-absorbable synthetic mesh (polypropylene, 
Prolene) 
0/31/0 NR 17m (3 – 48) Safety  
Efficacy 
 4 
ID N Age, y, median 
(range) or 
mean (range) 
Primary/ 
secondary repair, 
n 
Mesh/graft Anterior repair only/
posterior only/both, 
n 
Concomitant operation Follow-up, median 
(range) or mean 
(SD) 
Outcomes 
reported 
Anterior and/or posterior vaginal wall prolapse repair 
 
RCT (abs.) 
 
        
Allahdin 200621 
 
 
A, 32 
B, 34 
NR NR A, Absorbable synthetic mesh (polyglactin) 
B, no mesh 
NR Hysterectomy:  
A+B,14/66 
6m Efficacy 
Lim 200727 
 
 
 
A, 62 
B, 60 
NR NR A, non-absorbable synthetic mesh (polypropylene, 
Gynemsh PS) 
B, no mesh 
NR NR 1y Safety 
Efficacy  
Meschia 200728 
 
 
A, 36  
B, 35 
NR A, 36/0 
B, 35/0 
A, total mesh: non-absorbable synthetic mesh (Perigee-
Apogee system) 
B, no mesh 
NR NR 3m Safety 
Efficacy  
Non-randomised comparative studies 
 
Vakili 200536 
 
 
 
 
A, 98 
B, 214 
A, mean 65 
B, mean 61 
NR A, absorbable biological graft or non-absorbable 
synthetic mesh (>=1 type) 
B, no mesh 
A, 74/22/0 
B, NR 
Incontinence: 
A, 66/98; B, 142/214 
Hysterectomy: 
A, 7/98; B, 23/214 
9m (3 – 67) Safety  
Efficacy  
Registry  
 
        
Altman 200737 
 
 
71 NR 52/29 Non-absorbable synthetic mesh (polypropylene, Prolift, 
51 had total mesh) 
0/0/71 NR Registered in a 6m 
period 
Safety  
Case series 
 
        
Achtari 200539  
 
 
 
198 63 (11.6) NR Non-absorbable synthetic mesh (Polypropylene, Atrium, 
total mesh) or combined mesh (polypropylene and 
polyglactin) 
90/76/32 Incontinence: 67/198 
Hysterectomy: 13/198 
6w-6m safety 
Amrute 200740 
 
 
76 69 (11) NR Non-absorbable synthetic mesh (polypropylene, BioArc 
device, total mesh) 
0/0/76 Hysterectomy: 36/76 31m (2) Safety 
Efficacy  
Collinet 200641 
 
 
277 64 (37-81) NR Non-absorbable synthetic mesh (polypropylene, 169 
Prolene Soft, 108 Prolene) 
63/46/166 Incontinence: 136/277 
Hysterectomy: 164/277 
2m Safety  
 5 
 6 
ID N Age, y, median 
(range) or 
mean (range) 
Primary/ 
secondary repair, 
n 
Mesh/graft Anterior repair only/
posterior only/both, 
n 
Concomitant operation Follow-up, median 
(range) or mean 
(SD) 
Outcomes 
reported 
Cosson 200242 
 
 
83 47 (28-66) NR Non-absorbable synthetic mesh (polypropylene, 
Mersilene, total mesh) 
0/0/83 Incontinence: 74/83 
Hysterectomy: 60/83 
Mean 343d Safety  
Costantini 
200543 
 
72 61 (12) NR Non-absorbable synthetic mesh (polypropylene, Marlex, 
total mesh) 
0/0/72 Incontinence: 58/72 
Hysterectomy: 38/72 
51m (12 – 115) Safety 
Efficacy  
De Tayrac 
200745 
 
143 63 (37-91) NR Combined mesh/graft (polypropylene covered with 
atelocollagen) 
67/11/65 NR 13m (10-19) Safety 
Efficacy  
Dwyer 200447 
 
 
97 61 (30-86) NR Non-absorbable synthetic mesh (polypropylene, Atrium, 
some women had total mesh) 
47/33/17 Incontinence: 24/97 
Hysterectomy: 10/97 
29m (6-52) Safety 
Efficacy  
Fatton 200748 
 
 
110 63 (29-90) 88/22 Non-absorbable synthetic mesh (polypropylene, Prolene 
Soft, some women had total mesh) 
22/29/59 Incontinence: 45/110 
Hysterectomy: 15/110 
25w (12-42) Safety 
Efficacy 
Rozet 200461 
 
325 63 (35-78) NR Non-absorbable synthetic mesh (polyester covered 
silicone, total mesh) 
0/0/325 Incontinence: 163/325 
Hysterectomy: 15/325 
15m (6m-5y) Safety  
 719 
APPENDIX 2 Checklist of quality assessment of randomised controlled trials  720 
721  
Criteria Yes No Unclear Comment
1. Was the assignment to the treatment groups really 
random?  
 
    
2. Was the treatment allocation concealed from 
those responsible for entering patients into 
trials, i.e.  not knowing upcoming 
assignments in advance? 
 
    
3. Were the groups similar at baseline in terms 
of prognostic factors, e.g. age, duration of 
disease, disease severity?1 
    
4. Were the eligibility criteria specified?     
5. Was the intervention (and comparison) 
clearly defined?  
    
6. Were the groups treated in the same way 
apart from the intervention received? 
    
7. Was there a follow-up period ≥ 1 year?     
8. Was the outcome assessor blinded to the 
treatment allocation? 
    
9. If patient blind is possible, were the patients 
blinded?2 
    
10. If having primary outcome measures as 
continuous data, were the point estimates 
and measures of variability presented?3 
    
11. Were the withdrawals/drop-outs having 
similar characteristics as those completed 
the study and therefore unlikely to cause 
bias?4 
    
12. Did the analyses include all women 
according to randomised groups, i.e. 
intention-to-treat analysis?5 
    
13. Was the operation undertaken by somebody 
experienced in performing the procedure?6 
    
722 
723 
724 
725 
726 
727 
728 
729 
 
Note: 
 
1. ‘Yes’ if two or more than two factors were similar. 
2. If patient blinding is impossible, note ‘impossible’ in comment area and leave other 
cells blank. 
3. If having no primary outcome measures as continuous data, note ‘no continuous 
data’ in comment area and leave other cells blank. 
 1
730 
731 
732 
733 
4. ‘Yes’ if no withdrawal/drop out; ‘No’ if drop-out rate ≥30% or differential drop-out. 
5. ‘Yes’ if no withdrawals/drop out after enroll 
6. ‘Yes’ if the practitioner received training on conducting the procedure before or 
conducted same kind of procedure before, i.e. no learning curve.
 2
APPENDIX 3 Checklist of quality assessment of non-randomised studies 734 
735  
Criteria Yes No Unclear Comments
1.  Were participants a representative sample 
selected from a relevant patient population, 
e.g. randomly selected from those seeking 
for treatment despite of age, duration of 
disease, primary or secondary disease, 
and severity of disease? 
    
2. Were the inclusion/exclusion criteria of 
participants clearly described? 
    
3. Were participants entering the study at a similar 
point in their disease progression, i.e. severity of 
disease?  
    
4. Was selection of patients consecutive?      
5. Was data collection undertaken 
prospectively? 
    
6. Were the groups comparable on demographic 
characteristics and clinical features? 
    
7. Was the intervention (and comparison) 
clearly defined? 
    
8. Was the intervention undertaken by 
someone experienced at performing the 
procedure?1 
    
9. Were the staff, place, and facilities where 
the patients were treated appropriate for 
performing the procedure? (E.g.  access to 
back-up facilities in hospital or special 
clinic) 
    
10. Were all the important outcomes 
considered? 
    
11. Were objective (valid and reliable) outcome 
measures used, including satisfaction 
scale? 
    
12. Was the assessment of main outcomes 
blind? 
    
13. Was follow-up long enough (≥1y) to detect 
important effects on outcomes of interest? 
    
14. Was information provided on non-
respondents, dropouts?2 
    
15. Were the withdrawals/drop-outs having 
similar characteristics as those completed 
the study and therefore unlikely to cause 
bias?3  
    
 3
 4
16. Was length of follow-up similar between 
comparison groups 
    
17. Were all the important prognostic factors 
identified, e.g. age, duration of disease, 
disease severity?4 
    
18. Were the analyses adjusted for 
confounding factors? 
    
The same form was adapted to assess the quality of case series after taking out 
question 6, 12, 16 and 18. 
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Note: 
1. ‘Yes’ if the practitioner received training on conducting the procedure before or 
conducted same kind of procedure before, i.e. no learning curve.  
2. ‘No’ if participants were from those whose follow up records were available 
(retrospective) 
3. ‘Yes’ if no withdrawal/drop out; ‘No’ if drop-out rate ≥30% or differential drop-out, 
e.g. those having most severe disease died during follow up but the death was not 
due to treatment; no description of those lost. 
4. ‘Yes’ if two or more than two factors were similar. 
 
 
